Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis

Saleem, Hiba Muwafaq; Ramaiah, Pushpamala; Gupta, Jitendra; Jalil, Abduladheem Turki; Kadhim, Noor Abdulaala; Alsaikhan, Fahad; Ramírez-Coronel, Andrés Alexis; Tayyib, Nahla A; Guo, Qingdong

doi:10.1016/j.envres.2023.115942

Record: found
Abstract: not found
Article: not found

Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis

Author(s): Hiba Muwafaq Saleem , Pushpamala Ramaiah , Jitendra Gupta , Abduladheem Turki Jalil , Noor Abdulaala Kadhim , Fahad Alsaikhan , Andrés Alexis Ramírez-Coronel , Nahla A. Tayyib , Qingdong Guo

Publication date Created: September 2023

Publication date (Print): September 2023

Journal: Environmental Research

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 286

Record: found
Abstract: found
Article: not found

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp … (2017)

Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.

0 comments Cited 1372 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi-Long Wu, Iveta Kudaba … (2019)

First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.

0 comments Cited 1345 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron Mansfield, Aleksandra Szczęsna … (2018)

Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.